for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Bayer AG

BAYGn.DE

現在値

46.50EUR

変化

-0.02(-0.03%)

出来高

1,600,822

本日のレンジ

46.24

 - 

46.72

52週レンジ

39.91

 - 

57.73

∙ 約20分前の相場を表示しています。

適時開示

Bayer Says To Launch Organic Vegetable Seeds Portfolio

Sept 22 (Reuters) - Bayer AG <BAYGn.DE>::BAYER TO LAUNCH ORGANIC VEGETABLE SEEDS PORTFOLIO ENABLING GREATER ACCESS TO CERTIFIED ORGANIC MARKET.INITIAL PRODUCT OFFERING WILL FOCUS ON KEY CROPS FOR GREENHOUSE AND GLASSHOUSE MARKETS: TOMATO, SWEET PEPPER AND CUCUMBER.COMMERCIAL LAUNCH IS SLATED FOR 2022 IN CANADA, US, MEXICO, SPAIN AND ITALY WITH POTENTIAL FOR FUTURE EXPANSION.

Bayer Announces Positive Eliapixant Phase IIb Trial Results

Sept 6 (Reuters) - BAYER AG <BAYGn.DE>::BAYER'S ELIAPIXANT SIGNIFICANTLY DECREASED COUGH FREQUENCY IN PHASE IIB TRIAL IN PATIENTS WITH REFRACTORY CHRONIC COUGH.PRIMARY EFFICACY OUTCOME WAS MET SHOWING A STATISTICALLY SIGNIFICANT REDUCTION IN 24-HOUR COUGH COUNT (AVERAGE HOURLY COUGH FREQUENCY BASED ON 24-HOUR SOUND RECORDINGS) OF UP TO 27% FOR ELIAPIXANT 75 MG TWICE DAILY OVER PLACEBO AFTER 12 WEEKS OF TREATMENT.ELIAPIXANT DEMONSTRATED A POSITIVE BENEFIT-RISK PROFILE.DISCONTINUATION OF STUDY DUE TO ADVERSE EVENTS OCCURRED IN 8% OF PATIENTS TREATED WITH ELIAPIXANT.ELIAPIXANT MAY HAVE POTENTIAL FOR SAFE AND EFFECTIVE LONG-TERM USE.

Bayer Starts Phase III Clinical Program With Elinzanetant

Aug 31 (Reuters) - BAYER AG <BAYGn.DE>::STARTS PHASE III CLINICAL DEVELOPMENT PROGRAM OASIS WITH ELINZANETANT.PROGRAM INTENDS TO ENROLL APPROXIMATELY 1,300 PATIENTS AT MORE THAN 200 CENTERS IN OVER 20 COUNTRIES.

Bayer Says FDA Approves Expansion Of PAD Indication For Xarelto Plus Aspirin

Aug 24 (Reuters) - Bayer AG <BAYGn.DE>::U.S. FDA APPROVES EXPANSION OF THE PERIPHERAL ARTERY DISEASE (PAD) INDICATION FOR XARELTO™ PLUS ASPIRIN.FDA HAS APPROVED EXPANSION OF THE PERIPHERAL ARTERY DISEASE INDICATION FOR THE XARELTO VASCULAR DOSE TO INCLUDE PATIENTS FOLLOWING RECENT LOWER-EXTREMITY REVASCULARIZATION DUE TO SYMPTOMATIC PAD.Further company coverage: [BAYGn.DE]. (Gdansk Newsroom). ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;)).

Bayer says confident of reaching 2024 margin targets

Aug 5 (Reuters) - Bayer AG <BAYGn.DE>::SAYS CONFIDENT OF REACHING 2024 MARGIN TARGETS.SAYS WILL FILE ON AUG. 23 PETITION WITH U.S. SUPREME COURT SEEKING REVIEW OF LOWER COURT RULING THAT WENT IN FAVOUR OF ROUNDUP USER EDWIN HARDEMAN.SAYS WE EXPECT THAT SUPREME COURT WILL DECIDE BY LATE 2021/EARLY 2022 WHETHER OR NOT TO TAKE CASE.Further company coverage: <BAYGn.DE>. (Frankfurt newsroom). ((+49 69 7565 1270; Reuters Messaging: frankfurt.newsroom@thomsonreuters.net)).

France's CNIL data privacy watchdog fines Monsanto 400,000 euros

July 28 (Reuters) - French CNIL data privacy watchdog on Wednesday::IMPOSED A FINE OF 400,000 EUROS ON MONSANTO.FINE ON MONSANTO RELATES TO FAILING TO INFORM PEOPLE THAT THEIR PERSONAL DATA DETAILS MAY HAVE BEEN USED FOR LOBBYING PURPOSES.Further company coverage: [BAYGn.DE]. (Paris newsroom). ((+33 1 49 49 53 29;)).

Bayer's Chronic Heart Failure Treatment Verquvo Approved In EU

July 21 (Reuters) - BAYER AG <BAYGn.DE>::NEW SYMPTOMATIC CHRONIC HEART FAILURE TREATMENT VERQUVO (VERICIGUAT) APPROVED IN EU.IT WORKS DIFFERENTLY TO EXISTING HEART FAILURE TREATMENTS, PROVIDING A SPECIFIC APPROACH TO MANAGING CHRONIC HEART FAILURE PATIENTS FOLLOWING A DECOMPENSATION EVENT, ALSO KNOWN AS A WORSENING EVENT.APPROVED FOR ADULT PATIENTS WITH REDUCED EJECTION FRACTION WHO ARE STABILIZED AFTER A RECENT DECOMPENSATION EVENT REQUIRING INTRAVENOUS THERAPY.VERQUVO (VERICIGUAT) HAS BEEN APPROVED BY U.S. FOOD AND DRUG ADMINISTRATION (FDA) AND MINISTRY OF HEALTH, LABOUR, AND WELFARE (MHLW) IN JAPAN.VERICIGUAT HAS ALSO BEEN SUBMITTED FOR MARKETING AUTHORIZATION IN CHINA AS WELL AS MULTIPLE OTHER COUNTRIES WORLDWIDE.Further company coverage: [BAYGn.DE]. (Gdansk Newsroom). ((gdansk.newsroom@thomsonreuters.com; +48 58 769 6600;)).

Bayer AG U.S. FDA Approves Finerenone For Treatment Of Patients With Chronic Kidney Disease Associated With Type 2 Diabetes

Bayer AG <BAYGn.DE>::U.S. FDA APPROVES FINERENONE FOR TREATMENT OF PATIENTS WITH CHRONIC KIDNEY DISEASE ASSOCIATED WITH TYPE 2 DIABETES.

Bayer Says Rivaroxaban Application Submitted To U.S. FDA For Approval To Treat VTE

June 23 (Reuters) - BAYER AG <BAYGn.DE>::RIVAROXABAN APPLICATION SUBMITTED TO U.S. FDA FOR APPROVAL TO TREAT VTE AND TO PREVENT VTE IN CHILDREN.APPLICATION SEEKS TWO PEDIATRIC INDICATIONS, INCLUDING AN AGE-APPROPRIATE NEW WEIGHT-BASED ORAL SUSPENSION FORMULATION.IF APPROVED, XARELTO™ (RIVAROXABAN) WILL BE THE ONLY ORAL FACTOR XA INHIBITOR INDICATED IN THE U.S. FOR USE IN APPROPRIATE PEDIATRIC PATIENTS.Further company coverage: [BAYGn.DE]. (Gdansk Newsroom). ((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;)).

Bayer Submits Regulatory Applications For Oncology Treatment Combination Of Copanlisib And Rituximab In U.S. And EU

June 21 (Reuters) - BAYER AG <BAYGn.DE>::BAYER SUBMITS REGULATORY APPLICATIONS FOR ONCOLOGY TREATMENT COMBINATION OF COPANLISIB AND RITUXIMAB IN U.S. AND EU.ADDITIONALLY, FDA HAS GRANTED ORPHAN DRUG DESIGNATIONS (ODD) FOR COPANLISIB IN CLL)/SMALL LYMPHOCYTIC LYMPHOMA (SLL) AND LPL/WM.Further company coverage: [BAYGn.DE]. (Gdansk Newsroom). ((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;)).

金融情報はリフィニティブから。すべての情報は少なくとも20分遅れで表示されています。

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up